PEP-Therapy

Executive Summary

PEP-Therapy is a French clinical-stage biotechnology company developing first-in-class intracellular targeted peptide therapies for oncology. Its proprietary cell-penetrating drug delivery shuttle platform enables the intracellular delivery of therapeutic peptides, addressing previously undruggable targets. The lead candidate, PEP-010, is a pro-apoptotic peptide that disrupts protein-protein interactions to induce cancer cell death, currently in Phase Ia/b clinical trials for solid tumors. Founded in 2014 and based in Paris, the company is private with no disclosed funding or valuation. The platform has potential for broad applicability across multiple cancer types and other diseases. While still early-stage, the innovative delivery technology and initial clinical data are key value drivers.

Upcoming Catalysts (preview)

• Q2 2026Phase Ia dose-escalation data readout for PEP-01075% success
• Q3 2026Initiation of Phase Ib expansion cohort enrollment80% success
• TBDPotential financing or partnership for platform expansion50% success